Reading OMER? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OMER free→Reading OMER? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OMER free→QuarterlyIQ Insights · OMER
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 13, 2026, Omeros Corporation issued a press release announcing financial results for the three months ended March 31, 2026. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise sub…
Results of Operations and Financial Condition. On March 31, 2026, Omeros Corporation issued a press release announcing financial results for the three and twelve months ended December 31, 2025. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…
of Form 8-K, this filing is being made to report that at December 31, 2025, we had approximately $171.5 million of cash and short-term investments available for operations. This figure is preliminary and unaudited. It is subject to completion of the Company’s customary financial closing procedures and adjustments. The information in this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subj…
above are filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference: ● the Company’s unaudited pro forma condensed consolidated balance sheet as of September 30, 2025; ● the Company’s unaudited pro forma consolidated statement of operations and comprehensive income (loss) for fiscal year ended December 31, 2024; and ● the Company’s unaudited pro forma condensed consolidated statement of operations and comprehensive loss for the nine-month period ended Septe…
above. In addition, Omeros can receive (i) up to a total of $510 million in one-time milestone payments upon the first achievement by Novo Nordisk or its affiliates or sublicensees of each of the development and approval milestone events as set forth in the Agreement and (ii) up to $1.3 billion in one-time milestone payments upon the first achievement by Novo Nordisk or its affiliates or sublicensees of certain sales-based milestone events as set forth in the Agreement. The upfront cash recei…
Results of Operations and Financial Condition. On November 13, 2025, Omeros Corporation issued a press release announcing financial results for the three and nine months ended September 30, 2025. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
Entry into a Material Definitive Agreement. Asset Purchase and License Agreement On October 10, 2025, Omeros Corporation (the “Company”) entered into an Asset Purchase and License Agreement (the “Agreement”) with Novo Nordisk Health Care AG (“Novo Nordisk”), pursuant to which Novo Nordisk will receive exclusive global rights in all indications to develop and commercialize zaltenibart (OMS906), the Company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine prote…
Results of Operations and Financial Condition. On August 14, 2025, Omeros Corporation issued a press release announcing financial results for the three and six months ended June 30, 2025. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…
Other Events. Registered Direct Offering On July 24, 2025, Omeros Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Polar Asset Management Partners (the “Purchaser”) pursuant to which the Company agreed to issue and sell to the Purchaser in a registered direct offering (the “Offering”) an aggregate of 5,365,853 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a price per Share of $4.1…
Results of Operations and Financial Condition. On March 31, 2025, Omeros Corporation issued a press release announcing financial results for the three months and year ended December 31, 2024. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.